Early trial checks safety of blinatumomab in japanese leukemia patients
NCT ID NCT06649006
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested the safety of the drug blinatumomab (Blincyto®) in 6 Japanese adults newly diagnosed with a type of leukemia called B-ALL. The main goal was to see what side effects occurred. Researchers also looked at how the drug moves through the body and whether it helped achieve remission. Because it's a small, early trial, results are preliminary.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
blinatumomab (Blincyto®)
What this could lead to
If successful, this could support using blinatumomab as part of treatment for Japanese adults with B-ALL, potentially improving outcomes.
What could go wrong
This is a very small, early-phase trial (only 6 people) focused on safety, not effectiveness. Results may not apply to larger groups or show clear benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Akita University Hospital
Akita, Akita, 010-8543, Japan
-
Fukushima Medical University Hospital
Fukushima, Fukushima, 960-1295, Japan
-
Kanazawa University Hospital
Kanazawa, Ishikawa-ken, 920-8641, Japan
-
Kurume University Hospital
Kurume-shi, Fukuoka, 830-0011, Japan
-
Kyushu University Hospital
Fukuoka, Fukuoka, 812-8582, Japan
-
Yamagata University Hospital
Yamagata, Yamagata, 990-9585, Japan